InMed Pharmaceuticals Inc
INM
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.84M
Close$
$5.56
256.6% upside
Current Fair Value
256.6% upsideUndervalued by 256.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.84 Million |
|---|---|
| Enterprise Value | $-5,125,324,416.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-8.36 |
| Beta | 0.57 |
| Outstanding Shares | 4,048,209 |
Return
| Return on Equity | -27.54% |
|---|---|
| Return on Assets | -20.78% |
| Return on Invested Capital | -138.45% |
Valuation & Multiples
| P/E Ratio | -0.64 |
|---|---|
| PEG | 0.7 |
| Price to Sales | 0.0 |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | -0.68 |
| Enterprise Value to EBIT | 0.53 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | -0.01 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 18, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
September 18, 2026
EPS Estimate
$-94.44
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About InMed Pharmaceuticals Inc
20 employees
CEO: Eric Adams InMed Pharmaceuticals is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol ('CBN'), in diseases with high unmet medical need. T...